Clinical Study
Analysis of the application of atosiban in the fresh embryo transfer cycle in the test-tube baby program
Cheng Lanlan, Tan Li, Feng Zonggang, Wan Lijing
Published 2021-02-25
Cite as Chin J Reprod Contracep, 2021, 41(2): 125-130. DOI: 10.3760/cma.j.cn101441-20200303-00105
Abstract
ObjectiveTo explore the application of oxytocin receptor antagonist atosiban in the fresh embryo transfer cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) program.
MethodsWe selected 2349 fresh embryo transfer cycles, ranging from January 2016 to December 2019 in Reproductive Medicine Center, the Second Affiliated Hospital of Zhengzhou University. Patients were randomly categorized into atosiban group (1176 cycles) and control group (1173 cycles). The related indicators and clinical outcomes were compared between the two groups.
ResultsThe implantation rate [50.31% (1046/2079)], the clinical pregnancy rate [64.37% (757/1176)] and the live birth rate [53.17% (553/1040)] in atosiban group were remarkably higher than those of control group [39.09% (817/2090), 51.32% (602/1173), 41.01% (431/1051)], and the differences were significant statistically (allP<0.001). There were no differences in multiple pregnancy rate, multiple live birth rate, ectopic pregnancy rate and birth defect rate between the two groups (allP>0.05). Miscarriage rate of atosiban group [13.47% (102/757)] was lower than that of control group [16.44% (99/602)], but there was no significant difference (P>0.05).
ConclusionAtosiban could inhibit uterus contraction and peristalticus to improve implantation rate, clinical pregnancy rate and live birth rate, and atosiban did not increase the risk of birth defect in offspring. Therefore, application of oxytocin receptor antagonist atosiban could improve the clinical outcome in the fresh embryo transfer cycle of IVF/ICSI.
Key words:
Atosiban; Uterine contraction; Fertilization in vitro; Embryo transfer; Intracytoplasmic sperm injection; Clinical pregnancy rate; Live birth rate; Birth defect rate
Contributor Information
Cheng Lanlan
Reproductive Medical Center, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
Tan Li
Reproductive Medical Center, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
Feng Zonggang
Reproductive Medical Center, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
Wan Lijing
Reproductive Medical Center, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
本刊2021年第41卷第2期发表的《阿托西班在试管婴儿新鲜移植周期中的应用效果分析》一文，研究方法中关于阿托西班用法用量的表述有误。原文:“(醋酸阿托西班注射液37.5mg加500mL5%葡萄糖溶液中),滴速为2.5mL/h,匀速滴完。”更正为:"(醋酸阿托西班注射液37.5mg加入250mL0.9%氯化钠或5%葡萄糖溶液中)，1.5h匀速滴完。"对此作者深表歉意。更正的同时表示歉意！